Rivastigmine is indicated for the symptomatic treatment of mild to moderately severe Alzheimer's dementia and mild to moderately severe dementia in patients with idiopathic Parkinson's disease.

Rivastigmine is an acetyl- and butyrylcholinesterase inhibitor of the carbamate type, thought to facilitate cholinergic neurotransmission by slowing the degradation of acetylcholine released by functionally intact cholinergic neurones.

Active ingredient Pharmaceutical form Package Therapeutic target
  • Rivastigmine
  • Oral Solution (50ml, 120ml vials)
  • Hard Capsules
  • 2mg/ml
  • 1.5mg, 3mg, 4.5mg, 6mg
  • Central Nervous System-Alzheimer's Disease

Other products in "International"